linjc16/ctgov huggingface dataset:
Morquio's Syndrome: a Case Study

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: Relating about the benefits proportionated by the physiotherapeutic treatment for the patients that have the Morquio's syndrome. METHODS: This study intends to analyse a patient that presents this syndrome, describing the physiotherapeutic treatment that was proposed and the evolution clinical.

Official Title
-----------------
Morquio's Syndrome: a Case Study

Conditions
-----------------
Morquio's Disease

Intervention / Treatment
-----------------
* Other: physiotherapeutic treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The parents agreed with the study; The parents signed a consent term Exclusion Criteria: The treatment disturbed the patient physically or emotionally; The parents didn't signed the consent term; The patient refused to be treated.
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: A<br>A single case study, of a patient that was submitted to a physiotherapeutic treatment. | Other: physiotherapeutic treatment<br>* At first, the patient was submitted to a conventional physiotherapeutic treatment and respiratory exercises; then, we gave emphasis to the motor development marks and to the march training; eventually, the kid was conducted to hydrotherapy.<br>* Other names: physiatry;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Morquio's disease; physiotherapy; results
MRI Results in Dupuytren's Contracture Before and After Injection With Xiaflex

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the effects of XIAFLEX on your finger through MRI.

Detailed Description
-----------------
Collagenase injections for the treatment of Dupuytren's Contracture is a newly approved protocol which has shown early efficacy. There are very few studies which examine the MRI appearance of Dupuytren's disease. There are no studies that evaluate the condition of the cord after collagenase injection.

Official Title
-----------------
MRI Results in Dupuytren's Contracture Before and After Injection With Xiaflex

Conditions
-----------------
Dupuytren's Disease

Intervention / Treatment
-----------------
* Biological: XIAFLEX


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject has a diagnosis of Dupuytren's Disease affecting only the metacarpophalangeal joint of the 4th or 5th finger. Subject has only one finger affected by the disease. Patients will be 35 years of age of older. Patients will be able to read, speak, and understand English or have available adequate translation assistance and be able to provide voluntary written consent to participate. Exclusion Criteria: Female patients who are nursing or pregnant, or plan to become pregnant during the treatment phase. Patient has a chronic muscular, neurological or neuromuscular disorder that affects the hands. Patient has known allergy to collagenase or any other excipient of Xiaflex. Patient has received any collagenase treatments before the first dose of Xiaflex. Patient with abnormal coagulation, including patients who have received anticoagulant medications other than low-dose aspirin within 7 days of the injection.

Ages Eligible for Study
-----------------
Minimum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: XIAFLEX<br>XIAFlEX | Biological: XIAFLEX<br>* One Injection of 0.58 mg of Xiaflex into the affected area of the hand.<br>* Other names: Collagenase;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Measured Change in Volume of the Cord by MRI Before and After XIAFLEX Injection and Manual Manipulation. | Change in Volume (millimeter cubed) of the Cord by MRI between Baseline and 30 days after XIAFLEX injection and manual manipulation. | Baseline and 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dupuytren's Contracture
Treatment of Psoriasis Using Acitretin in HIV-Positive Patients

Study Overview
=================
Brief Summary
-----------------
To determine the efficacy of acitretin in the treatment of psoriasis in HIV/AIDS patients. Etretinate, a retinoid, has proven successful in the treatment of HIV-infected patients with psoriasis, but it has an elimination half-life of 100 days. Acitretin, a metabolite of etretinate, has a much shorter half-life of 2 to 3 days. Acitretin has proven effective in treating psoriasis in patients without HIV infection by reducing skin involvement and clearing of the condition, but it has not been thoroughly evaluated in HIV-infected patients.

Detailed Description
-----------------
Etretinate, a retinoid, has proven successful in the treatment of HIV-infected patients with psoriasis, but it has an elimination half-life of 100 days. Acitretin, a metabolite of etretinate, has a much shorter half-life of 2 to 3 days. Acitretin has proven effective in treating psoriasis in patients without HIV infection by reducing skin involvement and clearing of the condition, but it has not been thoroughly evaluated in HIV-infected patients. Patients receive acitretin daily, with dose increases every 4 weeks based on quantitative assessment of the skin using the Psoriasis Area and Severity Index (PASI). Treatment continues for a total of 20 weeks. Patients are followed every 2 weeks.

Official Title
-----------------
Treatment of Psoriasis Using Acitretin in HIV-Positive Patients

Conditions
-----------------
HIV Infections, Psoriasis

Intervention / Treatment
-----------------
* Drug: Acitretin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Concurrent Medication: Allowed: Any nondermatologic medication. Patients must have: HIV infection. Psoriasis involving at least 10 percent of body surface.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Acitretin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Psoriasis, Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Acitretin
Single Incision Laparoscopic Surgery (SILS) Versus Laparoscopic Cholecystectomy

Study Overview
=================
Brief Summary
-----------------
Prospective randomized trial of single incision versus standard 4 port laparoscopic cholecystectomy. Hypothesis is that the operative time will be longer with single incision.

Detailed Description
-----------------
This will be a prospective, randomized clinical trial involving patients who present to the hospital with an indication for cholecystectomy. We will offer enrollment to several institutions provided they receive institutional approval. This will be a definitive trial design. Based on our operative times with SILS compared with our recent experience in standard laparoscopy, a sample size of 60 patients will give us a power of 0.8 with an α of 0.05. After the procedure, both groups will be managed in the same manner per routine care. They will be discharged when tolerating a regular diet and their pain is well-controlled on oral pain medication.

Official Title
-----------------
Single Incision Versus Laparoscopic Cholecystectomy

Conditions
-----------------
Cholelithiasis, Biliary Dyskinesia

Intervention / Treatment
-----------------
* Procedure: SILS
* Procedure: Standard Laparoscopic Cholecystectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Need for cholecystectomy Exclusion Criteria: Need for cholangiogram

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: SILS Cholecystectomy<br>Single Incision Laparoscopic Cholecystectomy | Procedure: SILS<br>* Single Incision Laparoscopic Cholecystectomy<br>|
| Active Comparator: Standard Laparoscopic Cholecystectomy<br>4 port laparoscopic cholecystectomy | Procedure: Standard Laparoscopic Cholecystectomy<br>* 4 port technique<br>* Other names: Laparoscopic Cholecystectomy;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Operative Time |  | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Operative complications |  | 2 weeks | 
| length of hospitalization |  | 1 week | 
| doses of analgesics |  | 1 week | 
| hospital/operation charges |  | 1 week | 
| surgeon perception of difficulty |  | 1 day | 
| cosmetic scores |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SILS, Laparoscopic Cholecystectomy, Children
Study of 2 Doses of HRV Vaccine Given Concomitantly With Routine EPI Vaccinations Including OPV in Healthy Infants

Study Overview
=================
Brief Summary
-----------------
The main objectives of this study is to determine vaccine efficacy against severe rotavirus (RV) gastroenteritis (GE) during the period starting from 2 weeks after Dose 2 until one year of age.

Detailed Description
-----------------
The study has two groups: Group HRV and Group Placebo. Two oral doses administered to healthy infants who are 6-12 weeks of age at the time of Dose 1, according to a 0, 1 to 2-month schedule. Routine EPI vaccinations are given at the discretion of the investigator and according to local National Plans of Immunisation schedule in each participating country.

Official Title
-----------------
A Multi-country & Multi-center Study to Assess the Efficacy, Immunogenicity & Safety of Two Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine Given Concomitantly With Routine EPI Vaccinations Including OPV in Healthy Infants

Conditions
-----------------
Infections, Rotavirus

Intervention / Treatment
-----------------
* Biological: 2-dose oral live attenuated G1P[8] human rotavirus vaccine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Healthy infants 6 -12 weeks old at Dose 1 with written informed consent. Exclusion criteria: Allergic reaction to vaccine components; clinically significant history of chronic GI disease (uncorrected GI congenital malformation) or other serious medical condition per investigator, received vaccines or treatment prohibited by the protocol; immunocompromised.

Ages Eligible for Study
-----------------
Minimum Age: 6 Weeks
Maximum Age: 12 Weeks

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: 2-dose oral live attenuated G1P[8] human rotavirus vaccine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of severe RV GE caused by the wild RV strains during the period starting from 2 weeks after Dose 2 until 1 year old. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vaccine efficacy against severe rotavirus gastroenteritis by serotypes until 1 year of age; Safety; Immunogenicity of HRV and co-administered EPI vaccines |  |  |
Prevalence and Severity of Colour Vision Deficiency Among Turkish Children

Study Overview
=================
Brief Summary
-----------------
To evaluate the usability of the Colour Assessment and Diagnosis (CAD) test in children. To determine the prevalence of colour vision deficiency (CVD) among Turkish children, to identify the class of deficiency and to quanify severity of loss.

Official Title
-----------------
Prevalence and Severity of Colour Vision Deficiency Among Turkish Children

Conditions
-----------------
CAD Test; Children's Vision; Colour Assessment; Colour Vision; Turkey

Intervention / Treatment
-----------------
* Device: the Colour Assessment and Diagnosis (CAD) test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children with aged 6-16 years, who attended the ophthalmology department at the Istanbul Medipol University - Exclusion Criteria:Children with known or current evidence of ocular pathology (other than refractive errors), with history of long term use of medication, previous ocular surgery and those with chronic systemic diseases were excluded from the study -

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: the Colour Assessment and Diagnosis (CAD) test|The CAD test (City Occupational Ltd, London, UK) measures the severity of red-green and yellow-blue colour vision loss according to red-green and yellow-blue thresholds which are expressed in CAD units and diagnoses accurately the subject's class of colour vision|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence and Severity of Colour Vision Deficiency among Turkish Children | number of children with colour vision deficiency (CVD) among Turkish children who attend to the clinic in a period o time, number of children in each class of deficiency (protan, deutan) and number of children in each category according to severity. | january 2018-march 2019 | 
| the usability of the Colour Assessment and Diagnosis (CAD) test in children | number of children who were cooperative and carried out the full CAD test | january 2018-march 2019 |
Effect of Rocuronium on BIS Values

Study Overview
=================
Brief Summary
-----------------
Aim of this trial is to define if Trend of Four (TOF) values after a bolus of rocuronium is correlated with Bispectral Index BIS values during standard general anaesthesia for breast surgery.

Detailed Description
-----------------
Rocuronium. a curarizing agent, has been shown to decrease Bispectral Index (BIS) in awake volunteers. However, correlation between Trend of Four (TOF) values after a bolus of rocuronium and BIS values during general anaesthesia for breast surgery has not been defined yet. Investigators want to analyze this correlation during general anaesthesia conducted using Propofol and remifentanil. All of these drugs will be delivered with Targeted-Controlled Infusion pumps (in particular Eleveld for Propofol, Minto for Remifentanil), commonly used to deliver general anaesthesia. At stable anaesthesia maintenance, if requested for surgical (ie more muscle relaxation) or anesthesiological reasons (i.e. avoid air insufflation) a standard Rocuronium bolus (0.6 mg/kg) was given. In these case, with rocuronium bolus justified by clinical reasons, authors will observationally record the BIS values and the TOF values.

Official Title
-----------------
Correlation Between Trend of Four Values and Bispectral Index Values During General Anaesthesia for Breast Surgery.

Conditions
-----------------
Breast Cancer, General Anaesthesia

Intervention / Treatment
-----------------
* Drug: Rocuronium


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Undergo General Anaesthesia with Propofol and Remifentanil, and necessity of curarization with Rocuronium for surgical or ventilatory reasons. Exclusion Criteria: Neurological disease Psychiatric disease Benzodiazepines praemedication Obesity

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Rocuronium|Rocuronium bolus was administered, according to our protocol, to facilitate surgery and ventilation.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between Trend of Four (TOF) and Bispectral Index (BIS) values | Discover if there is linear correlation between TOF values (utilized for curarization monitoring) and BIS values (utilized for deep of hypnosis monitoring) during standard general anaesthesia conducted with Propofol and remifentanil with targeted controlled infusion pumps, usually adopted in our Hospital to delivery general anaesthesia | 60 minutes after rocuronium bolus |
Macroscopic and Molecular Changes in Knee Muscular - Tendon Unit in Response to Acute Resistant Load

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to determine whether individuals differ one from the other in their genetic, cellular, systemic, structural and functional response to acute exercise.

Official Title
-----------------
Macroscopic and Molecular Changes in Knee Muscular - Tendon Unit in Response to Acute Resistant Load

Conditions
-----------------
Physical Exertion

Intervention / Treatment
-----------------
* Other: Exercise
* Other: No exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy adults Exclusion Criteria: Unhealthy adults

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: No exercise<br>Volunteers will not participate in exercise | Other: No exercise<br>* Volunteers will not participate in exercise<br>|
| Active Comparator: Light exercise<br>Volunteers will participate in one short exercise | Other: Exercise<br>* Leg weight raising<br>|
| Active Comparator: Heavy exercise<br>Volunteers will participate in heavy exercise | Other: Exercise<br>* Leg weight raising<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Genetic polymorphism changes in knee muscles | Genetic analysis will be made through a blood test and biopsy of knee muscle and results will be compared | One year |
Barriers Affecting Physical Activity

Study Overview
=================
Brief Summary
-----------------
The goal of this research study is learn about how often cancer patients engage in physical activity using the exercise behavior questionnaire. This is an investigational study. Up to 200 participants will be enrolled in this study. All will take part at MD Anderson.

Detailed Description
-----------------
If participant agrees to take part in this study, participant will complete a series of questionnaires about exercise and participant's symptoms and physical abilities. These should take about 5 minutes to complete. Additionally, demographic information (such as participant's age, race, sex, zip code, specifics about participant's cancer type and care) will be collected from participant's medical record. Participant will complete the questionnaires 1 time, and participation in this study will be over after that.

Official Title
-----------------
Cancer Patients' Reported Frequency and Barriers to Physical Activity

Conditions
-----------------
Cancer Patients and Physical Activity

Intervention / Treatment
-----------------
* Behavioral: Questionnaires


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient must be 18 years of age or older. Patient must be able to understand, read, write and speak English. Patient must be able to sign an Informed Consent Form. Exclusion Criteria: Patients with physical limitations (visual, cognitive, motor impairment) causing inability to read, complete or sign the consent form and survey. Wheelchair bound patients who spend all of their day in bed or wheelchair Patients who the attending physician deems unable to participate due to acute physical distress. Previously filled out (EBBS and Stanford) surveys in the Supportive Care Clinic

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cancer Patients in Supportive Care Clinic (SCC)<br> | Behavioral: Questionnaires<br>* Participants complete a series of questionnaires about exercise, symptoms, and physical abilities. These should take about 5 minutes to complete.<br>* Other names: Surveys;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Cancer Patients Who Report Engaging in Physical Activity Using the Stanford Patient Education Research Center Exercise Behaviors Survey | Patients who report activity 1-3 hrs per week in any of the 6 questions or combination of any of these 6 questions are considered as engaging in physical activity | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Questionnaires, Surveys